Mandate

Vinge advises AstraZeneca on the sale of a pharmaceutical portfolio

June 04, 2007

Vinge is advising AstraZeneca on the sale of a large number of pharmaceuticals to Recip AB. The sale includes a portfolio of infection drugs for sale in Sweden, Norway, Denmark and Iceland. The annual sales of the 17 drugs included in the portfolio are SEK 240 million.

AstraZeneca is represented by partner Malin Leffler, assisted by Anna Berntsson and Claes Henriksson.

Related

Vinge advises Consolid Equity on the sale of Road Mobility Services to Nalka

Vinge has advised Consolid Equity on the sale of Road Mobility Services to Nalka. In connection with the transaction, Consolid, entrepreneurs and management will reinvest and remain as minority shareholders alongside Nalka as the new majority shareholder.
August 28, 2026

Vinge advises IK Partners and Selatek in connection with the acquisition of Jamo Sikring

Vinge advises IK Partners and their portfolio company Selatek AB ("Selatek") in connection with the acquisition of JAMO SIKRING A/S ("Jamo Sikring"), a Danish specialist in the installation, maintenance and ongoing inspection of fire protection systems. The acquisition marks Selatek's establishment of operations in Denmark and strengthens the group's position in fire safety and security services in the Nordics.
August 21, 2026

Vinge advises Xamera Group on the acquisition of the Finnish company Integrify

Xamera Group, partly owned by Helix Kapital, has acquired all the shares in the Finnish company Integrify, a leading Finnish provider of technology-focused and hire-purchase-based skills provision to the industrial, defence and tech sectors.
August 20, 2026